Key Points in the Implementation of Biopharmaceutical Technology Transfer
Key Points in the Implementation of Biopharmaceutical Technology Transfer No content available
NewsRoom
Going Global – Chime Biologics Embraces Innovation and Quality with Partners
Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]
CHO Cell Line Development: Process and Key Technical Points Overview
CHO Cell Line Development: Process and Key Technical Points Overview No content available
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]
Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry
Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry March 7, 2024, Wuhan, China – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items […]